Below you will find an overview of existing fitness news.
Analysis-Scientists analyze the avian flu pandemic in slow motion
Scientists tracking the spread of bird flu are concerned that gaps in surveillance may keep them several steps away from a new pandemic, according to Reuters interviews with more than a dozen leading disease experts. Many of them have been tracking the new H5N1 avian influenza subtype. in migratory birds since 2020. But the spread of the virus to 129 dairy herds in 12 U. S. states has been a major factor in the spread of the virus to 129 dairy herds in 12 U. S. states. The U. S. indicates a shift that may bring it closer to human-to-human transmission. Infections have also been detected in other mammals, from alpacas to domestic animals. Cats.
The Chinese robot’s “guide dog” seeks independence for the visually impaired
It’s less hairy than a classic companion, but a six-legged Chinese “advisory dog” robot could one day help other visually impaired people live more independently, according to its research and development team in Shanghai. Field-tested, it’s navigating your physical environment through cameras and sensors, adding traffic lights—anything classic consulting dogs can’t do.
South African Pharmacy Chain Clicks on Drug Manufacturer After Court Ruling
South African pharmacy chain Clicks Group announced on Monday that it will sell drugmaker Unicorn Pharmaceuticals to comply with a court order, paving the way for the Department of Health to consider corporate licenses for new stores. In March 2023, South Africa’s Constitutional Court ruled in favor of the Association of Independent Community Pharmacies (ICPA), which argued that Clicks’ ownership of Unicorn violated regulations that prohibited pharmacies from owning drug manufacturers.
Sanofi plans to invest up to $1. 6 billion in Germany, according to Handelsblatt
French drugmaker Sanofi is about to make a decision to invest between 1. 3 billion euros ($1. 4 billion and $1. 6 billion) in a primary production facility in Frankfurt, Germany, where it makes the Lantus insulin logo, the Handelsblatt newspaper reported on Monday. The newspaper cites German government sources as saying that Sanofi has changed course after having first thought about moving Lantus production to France and that the company is now about to embark on the modernization of the German plant located in Frankfurt’s Hoechst district.
Cancer victims lose attempt to block J bankruptcy project
A federal ruling on Friday rejected an attempt by a cancer organization to save Johnson from
Australia restricts e-cigarette sales to pharmacies as new laws come into force
New vaping regulations came into force in Australia on Monday, moving e-cigarette pharmacy counters in a bid to curb vaping among young people, although warring parties have forced the government to oppose a stricter ban. The laws, passed last week, will restrict sales of vaporizers to pharmacies and require consumers to talk to the pharmacist before buying a vaporizer. Those under 18 will need a prescription.
Bristol Myers to Pay $2. 7 Million to Settle Anticompetitive Tariffs in Israel
Bristol Myers Squibb has agreed to pay NIS 10 million ($2. 7 million) to Israel to settle an imaginable case over the blocking of a generic edition of the cancer drug Imnovid, Israel’s Competition Authority announced Monday. The antitrust firm said Bristol and Neopharm Scientific, the Israeli distributor of Imnovid, used for the treatment of multiple myeloma and AIDS-related Kaposi’s sarcoma, denied a request from KS Kim International for drug samples to create a copy edition of Imnovid.
EU Rapid Assessment on the Implementation of AstraZeneca COVID Prevention Medicines
AstraZeneca said on Monday that the European Union’s pharmaceutical regulator had accepted a marketing authorization application for its investigational COVID-19 prevention drug, sipavibart, for accelerated evaluation. The presentation was based on positive knowledge from a late-stage trial that showed the drug reduced the threat of infection in patients with diminished immunity.
Indian Panel Urges Drug Regulatory Body to Approve Lilly’s Anti-Obesity Drug Mounjaro
An Indian government-approved panel of experts has pleaded with the country’s pharmaceutical regulator to approve the import and sale of U. S. drugmaker Eli Lilly’s Mounjaro, a blockbuster diabetes drug and a popular obesity treatment, a document posted on a government website showed on Monday. Mounjaro, chemically known as tirzepatide, Zepbound’s Wegovy and Ozempic and its Danish rival Novo Nordisk belong to a series of treatments known as GLP-1 receptor agonists, evolved to blood sugar levels in patients with type 2 diabetes.
(This story was not edited by Devdiscourse staff and is automatically generated from a syndicated feed. )